Search our team at AdventHealth Research Institute
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT06500273
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective...
-
NCT06256484
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaTo characterize the safety and tolerability of ATA3219 monotherapy in subjects with R/R B-cell NHL. To determine the recommended phase 2 dose (RP2D) of ATA3219 as monotherapy in subjects with R/R B...
-
NCT04637763
CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaAllogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR...
-
NCT04416984
ALLO-501A-201: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL). (Alpha2 Study)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThere are 2 unapproved agents being evaluated in this study: ALLO-501A, and ALLO-647, which are used together and are being evaluated as a treatment for lymphoma. ALLO-647 is an antibody that will...
-
NCT04717414
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking...
-
NCT04137900
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma
This study is not currently enrolling.Associated Conditions: LymphomaResearch Area: Cancer ResearchThe purpose of this study is to determine the side effects of TAB004 (investigational drug) when given alone or in combination with toripalimab (another investigational drug), to determine a...